Effect of agomelatine on cognitive dysfunction in schizophrenia

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043512

Enrollment

Unknown

Registered

2021-02-21

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

schizophrenia group:Agomelatine

healthy control group:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of schizophrenia in the fourth edition of diagnostic and Statistical Manual of mental disorders; 2. Subjects with PANSS score of 1-3 and duration of more than 6 months; 3. Subjects without other diseases and family inheritance in the past; 4. Subjects who can communicate normally.

Exclusion criteria

Exclusion criteria: 1. Subjects with a history of drug dependence; 2. Alcohol dependent subjects; 3. Subjects who have used psychoactive substances; 4. Subjects who had received electroconvulsive therapy in the past 12 months; 5. Patients with endocrine diseases; 6. Patients with brain organic diseases; 7. Subjects with abnormal results of heart, liver, kidney function and blood routine examination.

Design outcomes

Primary

Measure	Time frame
PANSS;Wisconsin card sorting test;The Calgary Schizophrenia Depression Scale;	—

Countries

China

Contacts

Public ContactGuoping Zu

The Second Affiliated Hospital of Xinxiang Medical College

guopingzu@163.com+86 15936575993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026